Loading…
Employees: 337
Size Qyuns Therapeutics (2509.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $415M, the 805th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$14.33 on 6 Nov 2026.
Performance Over six months the shares fell 16.7%, against -19.0% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 8th highest of 20 in its peer set.
Growth Revenue grew 230.3% over the last twelve months (peer median +12.9%); the operating margin is 56.4% (peer median -10.1%).
Valuation It trades at 10.0× forward earnings against a peer median of 26.1× (cheapest of 6).
Capital Return on invested capital runs 88.2 points above its cost of capital (6.6% WACC).
Next results Next results expected around 26 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$1.14B | HK$875M | HK$172M | HK$0 | HK$0 |
| Revenue growth | — | +408% | — | — | — |
| Gross profit | HK$989M | HK$740M | HK$64.5M | -HK$35.7M | -HK$35.5M |
| EBITDA | HK$679M | HK$391M | -HK$354M | -HK$549M | -HK$353M |
| Net income | HK$607M | HK$341M | -HK$364M | -HK$561M | -HK$347M |
| Free cash flow | HK$549M | HK$414M | -HK$214M | -HK$352M | -HK$299M |
| Capital expenditure | HK$16.2M | HK$8.27M | HK$1.91M | HK$8.78M | HK$26.5M |
| Total debt | n/a | HK$646M | HK$561M | HK$381M | HK$331M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 2509.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -18.0% | -9.6% | 6th lowest of 21 |
| 6-month return | -16.7% | -19.0% | 8th highest of 20 |
| Distance from 52-week high | -48.4% | -44.7% | 9th lowest of 21 |
| Revenue growth (TTM) | +230.3% | +12.9% | 4th highest of 18 |
| Operating margin | 56.4% | -10.1% | highest of 18 |
| Forward P/E | 10.0× | 26.1× | cheapest of 6 |
| Growth the price implies (Req g, 7 yrs) | -20.2% | 4.9% | least demanding of 7 |
| ROIC minus cost of capital | +88.2 pp | -9.0 pp | highest of 16 |
| EV / EBITDA | 4.2× | 17.0× | 2nd cheapest of 5 |
| Net debt / EBITDA | -0.6× | -1.8× | 2nd most indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Qyuns Therapeutics 2509.HK | Hong Kong | $415M | -17% | +230% | 56% | 10.0× | -20.2% | n/a |
| CorMedix CRMD | United States | $415M | -33% | +280% | 47% | n/a | n/a | n/a |
| Kamada KMDA | United States | $417M | -15% | +11% | 14% | 15.8× | 4.1% | +6.5% |
| Beijing Kawin Technology Share-Holding 688687.SS | China | $410M | -19% | +3% | 0% | 17.0× | 43.0% | +8.9% |
| Arvinas ARVN | United States | $420M | -37% | -12% | -10% | n/a | n/a | n/a |
| Prothena PRTA | United States | $409M | -26% | +427% | -110% | n/a | n/a | n/a |
| Edding Genor 6998.HK | Hong Kong | $408M | -45% | +1,418% | 26% | n/a | -15.8% | +197.3% |
| Altimmune ALT | United States | $405M | -33% | +55% | -320,726% | n/a | n/a | n/a |
| Polynovo PNV.AX | Australia | $426M | -12% | +13% | 5% | 89.0× | 53.3% | +37.6% |
| EirGenix 6589.TW | Taiwan | $427M | +2% | +27% | -71% | n/a | n/a | n/a |
| Hubei Goto Biopharm 300966.SZ | China | $427M | -7% | +6% | -10% | n/a | n/a | n/a |
| Editas Medicine EDIT | United States | $395M | -17% | +21% | -178% | n/a | n/a | n/a |
| Zura Bio ZURA | United States | $394M | -15% | n/a | n/a | n/a | n/a | n/a |
| PureTech Health PRTC.L | United Kingdom | $394M | -8% | -4% | -1,617% | n/a | n/a | n/a |
| Ever Supreme Bio Technology 6712.TWO | Taiwan | $439M | +9% | +13% | 47% | 28.6× | 5.8% | +70.5% |
| TenNor Therapeutics Suzhou 6872.HK | Hong Kong | $440M | n/a | n/a | n/a | n/a | n/a | n/a |
| Onconic Therapeutics 476060.KS | South Korea | $391M | -45% | +179% | 21% | n/a | 2.0% | +725.2% |
| Beijing Luzhu Biotechnology 2480.HK | Hong Kong | $390M | -33% | n/a | n/a | 26.1× | n/a | n/a |
| Wuhan Hiteck Biological Pharma 300683.SZ | China | $443M | -36% | -30% | -27% | n/a | n/a | n/a |
| Shanghai Shen Lian Biomedical 688098.SS | China | $444M | -18% | -17% | -16% | n/a | n/a | n/a |
| Rznomics 476830.KS | South Korea | $386M | -79% | -72% | -1,440% | n/a | n/a | n/a |